List view / Grid view
Recent years have seen an increase in the development of biomaterial and nanoparticle-based vaccine formulations. Sushma Kumari, Sonal Asthana and Kaushik Chatterjee from the Department of Materials Engineering at the Indian Institute of Science discuss why these materials have such high potential in the fight against infectious diseases.
A new vaccine formulated with nanoparticles protected animal models from a variety of seasonal and pandemic influenza strains.
The natural language processing model trained using viral protein sequence data was able to predict promising targets for vaccines against HIV, influenza and coronaviruses.
A team has found immune cells in the lungs after infection from the flu, which protected mice against reinfection from a different strain.
According to researchers, an interaction between host microRNA and SARS-CoV-2 could be responsible for the range of disease severities.
Researchers have found that spermidine can ramp up autophagy and boost T-cell function, potentially increasing the protective effects of vaccines in older adults.
Scientists report their phage-based inhaled vaccine delivery system elicited a robust antibody response in both mice and non-human primates.
This article lists three of the most recent advances in pre-clinical HIV research and vaccine development.
After viral pneumonia in elderly mice, there is an accumulation of dysfunctional tissue-resident memory T cells in the lungs which scientists suggest may drive chronic inflammation and fibrosis.
Researchers have found that aprotinin, an approved drug for influenza in Russia, combats SARS-CoV-2 in cells.
Scientists reveal that coronaviruses de-activate lysosomes before using them to exit infected cells and spread through the body.
Using cryo-electron microscopy and site-specific mass spectrometry, researchers have mapped the glycans that shield HIV from the immune system.
A team showed that high doses of favipiravir can treat hamsters infected with SARS-CoV-2, whereas hydroxychloroquine has no effect.
A research team has developed a potentially universal flu vaccine that has demonstrated success in mice.
Researchers have screened small molecule libraries and then applied hit-to-lead approaches to discover effective vaccine adjuvants.
